跳至主要内容
临床试验/NCT06437639
NCT06437639已完成4 期

Prospective, Open, Comparative, Randomized Study of the Efficacy and Safety Evaluation of the Mexidol® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)

Pharmasoft1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2023年9月15日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Pharmasoft
入组人数
80
试验地点
1
主要终点
Degree of expression of mitochondrial dysfunction

研究概览

简要总结

Hypothesis: The use of neurocytoprotectors helps restore the functional activity of mitochondria, improve the nervous activity of the retina and optic nerve, and stabilize the glaucomatous process.

详细描述

Hypothesis

Mexidol® allows to optimize POAG therapy by reducing mitochondrial dysfunction and stabilizing glaucomatous optic neuropathy by improving the functional activity of mitochondria and its energy-producing function

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
50 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • An advanced stage of POAG in one or two eyes
  • Hypotonic-compensated intraocular pressure (IOP)

排除标准

  • Degenerative diseases of the central nervous system, diabetes mellitus
  • Primary mitochondrial dysfunction
  • A history of surgical interventions and damage to the organ of vision
  • Acute or chronic inflammatory or hereditary degenerative eye diseases (anterior and posterior sections)
  • Decompensation of concomitant somatic diseases
  • Taking antioxidants/nootropic drugs 6 months before inclusion in the study
  • Hypersensitivity to ethylmethylhydroxypyridine succinate or to any of the excipients

研究组 & 干预措施

Main (Mexidol and standard therapy)

Active Comparator

Mexidol IM 300 mg for 14 days, then Mexidol FORTE 250 orally 250 mg 1 tablet 3 times a day for 8 weeks; IOP normalizing therapy

干预措施: Mexidol (Drug)

结局指标

主要结局

Degree of expression of mitochondrial dysfunction

时间窗: 90 days

Enzyme status of lymphocytes (Succinate dehydrogenase and Glycerophosphate dehydrogenase)

Dynamics of the structural and functional characteristics of mitochondria

时间窗: 90 days

Cytomorphodensitometry (number of mitochondria, their optical density, number of granules and deposits in the mitochondria of lymphocytes)

次要结局

  • Structural and topographic changes in the layer of nerve fibers and the retinal ganglion [Optical Coherence Tomography (OCT) parameters](90 days)
  • Аssessment of differential light sensitivity of the retina(90 days)
  • Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability](90 days)

研究者

发起方
Pharmasoft
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

MEXIDOL® Sequential Therapy of Patients With Primary... | 临床试验